Overview Of Randomised Controlled Trials

A randomised controlled trial (RCT) is an interventional study design in which subjects are randomly allocated to different treatment options.

  • The RCT is widely considered the gold standard of individual medical research studies.
  • It generates reliable safety and efficacy data for health interventions such as drugs, diagnostic devices, and therapy protocols.
  • The primary goal is to assess the effect of an intervention against an active agent, an inert substance (placebo), or standard care.
  • RCTs limit the potential for bias by randomly assigning patient pools to different groups.
  • Random allocation ensures that the incidence of both known and unknown confounding factors is distributed equally between the groups.

Core Methodological Principles

graph TD
    A[Target Population] --> B[Experimental Population]
    B --> |Consent to participate| C[Study Participants / Sample]
    C --> D{Random Allocation}
    D --> E[Treatment Group: New Intervention]
    D --> F[Comparison Group: Standard Care / Placebo]
    E --> |Follow-up over time| G[Outcome Positive]
    E --> |Follow-up over time| H[Outcome Negative]
    F --> |Follow-up over time| I[Outcome Positive]
    F --> |Follow-up over time| J[Outcome Negative]

Randomization

  • Randomization refers to the random assignment of patients to the different treatments considered in the study.
  • It removes selection bias and produces balanced study groups.
  • Simple randomization: Each patient has a defined probability, usually 50/50, of receiving the new drug or the placebo.
  • Block randomization: Divides patients into blocks to ensure treatment and covariate balance during the recruitment phase.
  • Stratified randomization: Groups patients according to pre-specified covariate values (like gender or age) to form strata before randomizing, which reduces imbalance due to prognostic characteristics.

Allocation Concealment And Blinding

  • Allocation concealment: Prevents caregivers from knowing the group assignment prior to definitively allocating patients. It prevents preferential recruitment of unhealthier participants to a specific arm.
  • Blinding (Masking): Withholds information about treatment allocation from patients, treating physicians, or statisticians. It eliminates bias due to subjectivity in reporting or evaluating data.
Blinding TypeDescription
Open labelNo blinding is used. Both the patient and physicians know the treatment allocations.
Single blindedThe patient does not know what drug they are taking.
Double blindedBoth the patient and the investigator do not know which patient is receiving which treatment.
Triple blindedThe patient, investigator, and the biostatistician analyzing the data are kept unaware of the allocations.

Types Of RCTs Based On Structural Design

RCTs can utilize different structural designs based on the nature of the intervention and disease.

Parallel Design

  • Patients are randomized to one of the treatment groups.
  • Each patient receives only one type of treatment.
  • It is the most common structural design for clinical trials.

Cross-Over Design

  • Each participant is exposed to both the control and the intervention in a sequence.
  • Each individual serves as his or her own control.
  • It requires a washout period to eliminate carry-over effects from the first treatment.
  • The analysis is complex, but it allows for a smaller sample size.

Factorial Design

  • Tests the effect of more than one treatment simultaneously.
  • A 2x2 factorial design involves four groups (e.g., A only, B only, A + B, neither).
  • It allows the assessment of potential interactions among the treatments.

Cluster Randomized Trials

  • Groups or clusters of individuals are randomly allocated rather than individual subjects.
  • The unit of randomization can be families, schools, or geographical areas.
  • It is used to avoid treatment contamination among participants.
  • The statistical analysis is more complex as it must account for the clustering effect.

N-Of-1 Trials

  • Trials in which a single patient is treated with two or more treatments on multiple occasions.
  • The objective is to use these repeated episodes to draw controlled inferences about the effect of the treatment on that individual.
  • It can be viewed as a special case of the crossover design.

Types Of RCTs Based On Hypothesis Objectives

Trials are also classified based on what the researchers are aiming to prove regarding the new intervention.

Superiority Trials

  • The aim is to prove that the new drug is better (more efficacious) than a placebo or current treatment.
  • It must have adequate statistical power to detect a clinically meaningful difference between the two treatments.

Non-Inferiority Trials

  • The aim is to prove that the new drug is no worse than the current standard treatment.
  • The treatment must not be worse than the control by a pre-specified amount referred to as the non-inferiority margin.
  • Often used when a new drug might offer secondary benefits like lesser toxicity, cheaper cost, or easier administration.

Equivalence Trials

  • The aim is to determine whether one intervention is therapeutically similar to another.
  • The hypothesis tests whether the treatment effect lies within a pre-defined equivalence margin.

Types Of RCTs Based On Pragmatism

Explanatory Trials

  • Designed strictly to explain how a treatment works.
  • Investigators set strict inclusion criteria to produce highly homogeneous study groups.
  • The aim is to acquire information on the true effect of treatment under ideal conditions.

Pragmatic Trials

  • Designed to determine whether a treatment works and to describe all consequences of its use under circumstances close to real clinical practice.
  • They use more lax inclusion criteria and tend to use active controls rather than placebo controls.
  • The aim is to make a practical decision about the therapeutic strategy.

Phases Of Clinical Trials

Clinical trials evaluating new pharmaceutical interventions progress through four sequential phases.

  • Phase I: Initial clinical trial on a new compound, usually conducted among healthy volunteers to assess safety and determine the maximum tolerated dose.
  • Phase II: Conducted in patients to determine the optimum dose and to assess the short-term efficacy of the compound.
  • Phase III: Large multicenter comparative clinical trials. Designed to demonstrate the safety and efficacy of the new treatment with respect to standard treatments to support product license applications.
  • Phase IV: Post-marketing studies conducted after a drug is marketed to provide additional details about long-term safety, efficacy, and usage profiles.

Statistical Analysis Methods In RCTs

Handling patient attrition and protocol non-compliance is critical in RCT analysis.

Analysis MethodDescriptionCharacteristics
Intention-To-Treat (ITT)Analyzes all patients based on their original allocated group regardless of the actual treatment received or dropouts.Preserves the benefits of randomization. Provides a pragmatic estimate of the population-level effect.
Per-Protocol AnalysisAnalyzes only the patients who strictly complied with the trial protocol and the allocated intervention.Evaluates the effect of adherence to treatment assignment. Highly susceptible to confounding bias.
As-Treated AnalysisPatients are analyzed according to the actual treatment they received, ignoring original allocation.Gives the maximum estimate of treatment effects but is extremely vulnerable to selection bias.

Advantages And Disadvantages Of RCTs

Advantages

  • Provides stronger evidence compared to observational studies.
  • Demonstrates causality effectively.
  • Randomization controls for both measured and unmeasured confounding variables.
  • Serves as the gold standard for generating scientific evidence for new interventions.

Disadvantages

  • Trials can be very costly and require extensive resources.
  • Long follow-up periods might be needed for certain clinical outcomes.
  • Non-compliance, treatment cross-over, or loss to follow-up (attrition) severely affects validity.
  • Ethical and practical considerations sometimes make RCTs impossible to conduct.
  • Concerns exist regarding external validity (generalizability) because highly selected trial participants may not fully represent the general population.